

Specification with Markings to Show Changes Made

Please amend the Specification as follows:

On page 12, please replace the title of Example 2 on line 16 with the following:

--EXAMPLE 2: Synthesis and purification of hydrazinopeptide 6 (which includes RGRILKEPVHGV) (SEQ ID NO. 1) (Fig. 2).--

On page 12, please replace the paragraph beginning on line 19 with the following:

-- Peptide 5 (SEQ ID NO. 5) produced on a Wang resin(0.73 mmol/g, Applied Biosystems, Foster City, USA), using the Fmoc/*tert*-butyl strategy, as described, for example, by FIELDS *et al.* in *Int. J. Pept. Protein*, 1990, 35, 161, and HBTU/Hobt activation (see SCHNÖLZER *et al* in *Int. J. Pept. Protein Res.*, 1992, 40, 180) using a 431A Applied Biosystem peptide synthesizer (Foster City, USA). Protection of the side chains is provided by: His(Trt), Glu(O<sup>t</sup>Bu), Arg(Pmc), Lys(Boc) (SEQ ID NO. 6). Upon completion of the synthesis, the Fmoc group of the  $\alpha$ -NH<sub>2</sub> function of the arginine is displaced in the presence of 20% piperidine in the DMF. The N,N'-tri(Boc)hydrazinoacetic acid 4 (1.2 eq) is then introduced manually using BOP activation *in situ* (BOP 1.2 eq, DIEA 3.6 eq in the DMF for 20 minutes), as described, for example, by GAIRI *et al.* in *Tetrahedron Letters*, 1990, 50, 7363. Alternatively, N,N'-di(Boc)-hydrazinoacetic acid could also be used. The peptidyl-resin is washed successively with DMF, dichloromethane, and then with ether. It is then dried at reduced pressure for 30 minutes.--

On page 16, please replace the header 1) on line 5 with the following:

--1) Synthesis of hydrazinopeptide 19( which includes VGFFKR)  
(SEQ ID NO. 2)–

On page 16, please replace the header 2) on line 29 with the following:

--2) Synthesis of lipopeptide 21(which includes KVGFFKR) (SEQ ID  
NO. 3)–

On page 17, please replace the header 1) on line 3 with the following:

--1) Synthesis of hydrazinopeptide 22 (which includes  
AKFEVNNPQVQRQAFNELIRVVHQLLPESLRKRKRSR) (SEQ ID NO. 4).

On page 17, please replace the paragraph beginning on line 4 with the following:

-- Peptide 22 is prepared on a Fmoc-PAL-PEG-PS resin (0.16 mmol/g, Perseptive) according to the Fmoc/*tert*-butyl strategy and an HBTU/HOBt activation (see example 2) on a Pioneer-Perseptive peptide synthesizer. Protection for the side chains of the amino acids is as follows: His(Trt), Asn(Trt), Glu(O<sup>t</sup>Bu), Arg(Pbf), Lys(Boc), Ser(<sup>t</sup>Bu) (SEQ ID NO. 7). Upon completion of synthesis, the Fmoc group of the  $\alpha$ -NH<sub>2</sub> function of the alanine is removed in the presence of piperidine at 20% in the DMF. The N,N'-tri(Boc)hydrazinoacetic acid (1.2 eq.) is then introduced manually using BOP activation *in situ* (BOP: 1.2 eq., DIEA: 3.6 eq. In the DMF for 20 minutes). The peptidyl-resin is washed successively with DMF, dichloromethane, and then ether. It is then dried at reduced pressure for 30 minutes. Cleavage of the peptide-resin link as well as deprotection of the side chains

are carried out in the presence of a TFA/phenol/ethanedithiol/thioanisole/H<sub>2</sub>O mixture (1 g of dry resin/10 ml of TFA/ 0.25 ml of ethanedithiol/0.25 ml of H<sub>2</sub>O/0.25 ml of thioanisole/0.75 g of phenol) with stirring for 3h30 at ambient temperature. The peptide is precipitated in 200 ml of an Et<sub>2</sub>O/heptane mixture (1/1) previously cooled down to 0°C. The precipitate is centrifuged and then dissolved in an H<sub>2</sub>O/AcOH mixture (5/1), deep frozen and freeze dried, 263 mg of raw peptide are obtained from 0.072 mmole of resin.-

Please replace the second paragraph on page 18 starting at line 8 with the following:

--Peptide 22 and lipopeptide 23 were prepared as indicated in example 6. Peptide 22Sc ("scramble" version of peptide 22) has the following sequence: H<sub>2</sub>N-NH-CH<sub>2</sub>CO-

PSRENQNAVKIQKLSVVLRRREQKHRVERLAFRNQSLPF-NH<sub>2</sub> (SEQ ID NO. 8).-